Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Charles River Laboratories Intl (CRL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,010,688
  • Shares Outstanding, K 47,360
  • Annual Sales, $ 1,681 M
  • Annual Income, $ 154,770 K
  • 36-Month Beta 0.88
  • Price/Sales 2.77
  • Price/Cash Flow 14.66
  • Price/Book 5.01

Price Performance

See More
Period Period Low Period High Performance
1-Month
104.00 +2.86%
on 01/22/18
112.47 -4.89%
on 01/09/18
-1.54 (-1.42%)
since 12/22/17
3-Month
99.12 +7.92%
on 11/15/17
119.05 -10.15%
on 11/02/17
-7.94 (-6.91%)
since 10/23/17
52-Week
77.61 +37.83%
on 01/30/17
119.05 -10.15%
on 11/02/17
+27.55 (+34.69%)
since 01/23/17

Most Recent Stories

More News
Charles River Laboratories Adds Jean-Paul Mangeolle to Board of Directors

Charles River Laboratories International, Inc. (NYSE:CRL) today announced the appointment of Jean-Paul Mangeolle, former President of AB SCIEX, to its Board of Directors. Mr. Mangeolle's...

CRL : 106.97 (+1.11%)
Charles River Laboratories Acquires KWS BioTest

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has acquired KWS BioTest, a leading contract research organization (CRO) specializing in in vitro and in...

CRL : 106.97 (+1.11%)
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday,...

JPM : 114.21 (-0.10%)
CRL : 106.97 (+1.11%)
Free Post Earnings Research Report: Charles River's Revenue Grew 9%; EPS Surged 36.7%

Stock Monitor: iKang Healthcare Post Earnings Reporting

CRL : 106.97 (+1.11%)
KANG : 16.02 (+0.88%)
Quotidian Technical Highlights on Selected Medical Research Stocks -- Thermo Fisher Scientific, Agilent Technologies, IQVIA, and Charles River Labs

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on TMO, A, IQV, and CRL which is a click away at www.wallstequities.com/registration....

A : 73.44 (-0.05%)
TMO : 214.55 (-0.36%)
CRL : 106.97 (+1.11%)
IQV : 103.21 (+0.36%)
Investor Expectations to Drive Momentum within CatchMark Timber Trust, Global Payments, Charles River Laboratories International, Tile Shop Hldgs, Cytokinetics, and Limelight Networks -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CatchMark Timber Trust,...

CTT : 13.24 (+0.84%)
TTS : 10.05 (-1.95%)
CYTK : 10.05 (+5.24%)
GPN : 109.89 (+0.72%)
LLNW : 4.44 (+0.68%)
CRL : 106.97 (+1.11%)
Charles River Announces Success of Integrated Discovery Project with ENYO Pharma

Charles River Laboratories International, Inc. (NYSE: CRL) and ENYO Pharma SA today announced the results of a successful collaboration. Together, the companies identified the mode of action...

CRL : 106.97 (+1.11%)
Earnings Review and Free Research Report: Labcorp's Revenue Jumped 9.5%; Raised Outlook for 2017

Research Desk Line-up: Charles River Laboratories Post Earnings Coverage

LH : 175.78 (-0.27%)
CRL : 106.97 (+1.11%)
Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations

--- Third-Quarter GAAP EPS of $1.09 and Non-GAAP EPS of $1.30 -

CRL : 106.97 (+1.11%)
Why Earnings Season Could Be Great for Charles River Laboratories (CRL)

Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

CRL : 106.97 (+1.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Their dedicated employees are focused...

See More

Key Turning Points

2nd Resistance Point 109.40
1st Resistance Point 108.19
Last Price 106.97
1st Support Level 105.57
2nd Support Level 104.16

See More

52-Week High 119.05
Last Price 106.97
Fibonacci 61.8% 103.22
Fibonacci 50% 98.33
Fibonacci 38.2% 93.44
52-Week Low 77.61

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.